"A study involving Eli Lilly & Co.'s experimental drug evacetrapib showed it was able to boost good cholesterol levels while lowering the bad kind," writes Jennifer Corbett Dooren for the Wall Street Journal.

"The study was presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla., and published in the Journal of the American Medical Association. It was funded by Eli Lilly and led by doctors at the Cleveland Clinic."

Evacetrapib is designed to inhibit cholesteryl ester transfer protein, or CETP, which is involved in transferring cholesterol particles from HDL -- the "good" cholesterol -- to LDL, referred to as "bad" cholesterol.

Read the rest here.